Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electroretinography | 28 | 2023 | 57 | 5.560 |
Why?
|
| Retina | 22 | 2023 | 130 | 4.150 |
Why?
|
| Retinal Ganglion Cells | 22 | 2023 | 100 | 4.070 |
Why?
|
| Evoked Potentials, Visual | 6 | 2018 | 19 | 2.390 |
Why?
|
| Glaucoma | 9 | 2023 | 40 | 2.190 |
Why?
|
| Nerve Fibers | 10 | 2023 | 55 | 2.120 |
Why?
|
| Photic Stimulation | 23 | 2023 | 136 | 2.020 |
Why?
|
| Multiple Sclerosis | 5 | 2018 | 44 | 1.960 |
Why?
|
| Visual Fields | 9 | 2023 | 67 | 1.960 |
Why?
|
| Optic Neuritis | 6 | 2015 | 14 | 1.690 |
Why?
|
| Vision Disorders | 6 | 2018 | 43 | 1.550 |
Why?
|
| Tomography, Optical Coherence | 11 | 2023 | 217 | 1.490 |
Why?
|
| Visual Pathways | 5 | 2011 | 19 | 1.290 |
Why?
|
| Contrast Sensitivity | 3 | 2018 | 64 | 1.280 |
Why?
|
| Animals | 34 | 2023 | 1711 | 1.270 |
Why?
|
| Optic Nerve Diseases | 7 | 2019 | 29 | 1.270 |
Why?
|
| Retinal Cone Photoreceptor Cells | 8 | 2023 | 35 | 1.260 |
Why?
|
| Optic Disk | 4 | 2023 | 59 | 1.230 |
Why?
|
| Retinal Rod Photoreceptor Cells | 7 | 2023 | 20 | 1.220 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 225 | 1.210 |
Why?
|
| Color Vision | 3 | 2023 | 11 | 1.120 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2014 | 8 | 1.050 |
Why?
|
| Female | 20 | 2023 | 2523 | 0.840 |
Why?
|
| Adult | 16 | 2019 | 1567 | 0.810 |
Why?
|
| Male | 20 | 2020 | 2491 | 0.760 |
Why?
|
| Visual Field Tests | 7 | 2015 | 39 | 0.740 |
Why?
|
| Dark Adaptation | 5 | 2013 | 6 | 0.730 |
Why?
|
| Axons | 3 | 2018 | 17 | 0.690 |
Why?
|
| Macaca mulatta | 13 | 2023 | 111 | 0.640 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2010 | 4 | 0.630 |
Why?
|
| Middle Aged | 10 | 2019 | 967 | 0.630 |
Why?
|
| Humans | 20 | 2022 | 4936 | 0.600 |
Why?
|
| Clinical Protocols | 1 | 2018 | 4 | 0.570 |
Why?
|
| Mice | 11 | 2016 | 685 | 0.530 |
Why?
|
| Retinal Neurons | 2 | 2014 | 4 | 0.500 |
Why?
|
| Nerve Degeneration | 2 | 2014 | 8 | 0.500 |
Why?
|
| Receptors, GABA | 1 | 2015 | 1 | 0.460 |
Why?
|
| Retinal Diseases | 1 | 2015 | 13 | 0.460 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 73 | 0.440 |
Why?
|
| DNA | 1 | 2015 | 58 | 0.440 |
Why?
|
| Mice, Inbred C57BL | 9 | 2016 | 184 | 0.440 |
Why?
|
| Tetrodotoxin | 8 | 2011 | 9 | 0.430 |
Why?
|
| Mammals | 1 | 2013 | 18 | 0.410 |
Why?
|
| Pipecolic Acids | 7 | 2009 | 9 | 0.390 |
Why?
|
| Intraocular Pressure | 4 | 2023 | 62 | 0.380 |
Why?
|
| Retinal Detachment | 2 | 2023 | 3 | 0.370 |
Why?
|
| Optic Nerve Injuries | 3 | 2020 | 6 | 0.360 |
Why?
|
| Young Adult | 6 | 2019 | 787 | 0.350 |
Why?
|
| Sodium Channels | 2 | 2008 | 5 | 0.350 |
Why?
|
| Societies, Medical | 2 | 2022 | 7 | 0.330 |
Why?
|
| Adaptation, Ocular | 4 | 2017 | 9 | 0.320 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2009 | 20 | 0.310 |
Why?
|
| Nerve Tissue Proteins | 3 | 2007 | 34 | 0.310 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2006 | 9 | 0.290 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2019 | 5 | 0.290 |
Why?
|
| Papilledema | 2 | 2019 | 14 | 0.290 |
Why?
|
| Synapses | 4 | 2023 | 10 | 0.280 |
Why?
|
| Night Blindness | 1 | 2008 | 1 | 0.280 |
Why?
|
| Retinal Degeneration | 1 | 2009 | 38 | 0.280 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2007 | 28 | 0.260 |
Why?
|
| Case-Control Studies | 3 | 2014 | 81 | 0.260 |
Why?
|
| Macaca | 3 | 2021 | 11 | 0.250 |
Why?
|
| Bruch Membrane | 2 | 2023 | 19 | 0.230 |
Why?
|
| Sodium Channel Blockers | 3 | 2011 | 4 | 0.230 |
Why?
|
| Rats | 3 | 2015 | 241 | 0.230 |
Why?
|
| Reaction Time | 3 | 2010 | 52 | 0.220 |
Why?
|
| rho-Associated Kinases | 2 | 2023 | 8 | 0.220 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2004 | 18 | 0.210 |
Why?
|
| Aminobutyrates | 4 | 2009 | 5 | 0.210 |
Why?
|
| Vesicular Transport Proteins | 1 | 2003 | 2 | 0.210 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 12 | 0.210 |
Why?
|
| Carrier Proteins | 1 | 2003 | 23 | 0.200 |
Why?
|
| Neural Pathways | 1 | 2003 | 31 | 0.200 |
Why?
|
| Eye Proteins | 1 | 2003 | 36 | 0.200 |
Why?
|
| Primates | 1 | 2023 | 8 | 0.200 |
Why?
|
| Membrane Proteins | 1 | 2003 | 47 | 0.200 |
Why?
|
| Cell Differentiation | 1 | 2003 | 71 | 0.200 |
Why?
|
| Sensory Thresholds | 1 | 2002 | 23 | 0.190 |
Why?
|
| N-Methylaspartate | 4 | 2007 | 9 | 0.180 |
Why?
|
| Linear Models | 2 | 2014 | 58 | 0.180 |
Why?
|
| Disease Progression | 2 | 2014 | 59 | 0.180 |
Why?
|
| Time Factors | 2 | 2014 | 163 | 0.170 |
Why?
|
| Electrophysiology | 2 | 2021 | 24 | 0.170 |
Why?
|
| Models, Animal | 1 | 2021 | 24 | 0.170 |
Why?
|
| Eye Injuries | 1 | 2021 | 4 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 25 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 30 | 0.160 |
Why?
|
| ROC Curve | 3 | 2019 | 26 | 0.150 |
Why?
|
| Nerve Crush | 3 | 2020 | 5 | 0.150 |
Why?
|
| Ophthalmology | 1 | 2018 | 2 | 0.140 |
Why?
|
| Light | 4 | 2017 | 43 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2017 | 20 | 0.140 |
Why?
|
| Electrooculography | 1 | 2017 | 2 | 0.130 |
Why?
|
| Cells, Cultured | 2 | 2015 | 127 | 0.130 |
Why?
|
| Leukocyte Rolling | 1 | 2016 | 1 | 0.130 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Receptors, CXCR3 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2017 | 21 | 0.130 |
Why?
|
| Eye Diseases | 1 | 2017 | 16 | 0.130 |
Why?
|
| Accommodation, Ocular | 2 | 2009 | 36 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 269 | 0.120 |
Why?
|
| Strongylocentrotus purpuratus | 1 | 2016 | 1 | 0.120 |
Why?
|
| Transcription Factor Brn-3B | 1 | 2016 | 1 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 7 | 0.120 |
Why?
|
| Synaptic Transmission | 2 | 2008 | 13 | 0.120 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2016 | 39 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2007 | 6 | 0.120 |
Why?
|
| Fourier Analysis | 2 | 2006 | 11 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 126 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 125 | 0.110 |
Why?
|
| Aging | 2 | 2008 | 109 | 0.110 |
Why?
|
| Adolescent | 2 | 2012 | 758 | 0.110 |
Why?
|
| Macula Lutea | 1 | 2014 | 17 | 0.110 |
Why?
|
| Tonometry, Ocular | 1 | 2014 | 39 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 60 | 0.100 |
Why?
|
| Interneurons | 2 | 2003 | 6 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2009 | 7 | 0.100 |
Why?
|
| Logistic Models | 1 | 2014 | 64 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 137 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2013 | 75 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 318 | 0.100 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 49 | 0.090 |
Why?
|
| Aged | 2 | 2014 | 703 | 0.090 |
Why?
|
| Scanning Laser Polarimetry | 1 | 2012 | 3 | 0.090 |
Why?
|
| Swine | 2 | 2023 | 50 | 0.090 |
Why?
|
| Intravitreal Injections | 1 | 2011 | 5 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 83 | 0.090 |
Why?
|
| Action Potentials | 1 | 2011 | 18 | 0.090 |
Why?
|
| Trabecular Meshwork | 1 | 2011 | 6 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2011 | 7 | 0.090 |
Why?
|
| Ocular Hypertension | 1 | 2011 | 11 | 0.090 |
Why?
|
| Guinea Pigs | 2 | 2021 | 10 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2011 | 161 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2008 | 25 | 0.080 |
Why?
|
| Injections | 3 | 2007 | 9 | 0.080 |
Why?
|
| Myelin Sheath | 1 | 2010 | 3 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2009 | 22 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2009 | 18 | 0.080 |
Why?
|
| Vision, Ocular | 2 | 2022 | 34 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2009 | 30 | 0.070 |
Why?
|
| Cysteamine | 1 | 2008 | 2 | 0.070 |
Why?
|
| Transfection | 1 | 2008 | 15 | 0.070 |
Why?
|
| Neuroglia | 1 | 2008 | 8 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 14 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 26 | 0.070 |
Why?
|
| Rats, Inbred BN | 1 | 2008 | 3 | 0.070 |
Why?
|
| Peptides | 1 | 2008 | 49 | 0.070 |
Why?
|
| Proteins | 1 | 2008 | 46 | 0.070 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 6 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2010 | 179 | 0.070 |
Why?
|
| Receptors, Glutamate | 1 | 2007 | 3 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 39 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2007 | 25 | 0.070 |
Why?
|
| Retinoscopy | 1 | 2007 | 6 | 0.070 |
Why?
|
| Ophthalmoscopy | 1 | 2007 | 10 | 0.070 |
Why?
|
| Protein Isoforms | 2 | 2003 | 13 | 0.060 |
Why?
|
| Image Enhancement | 1 | 2007 | 46 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2019 | 341 | 0.060 |
Why?
|
| Sclera | 1 | 2007 | 57 | 0.060 |
Why?
|
| Oscillometry | 1 | 2006 | 6 | 0.060 |
Why?
|
| Cell Count | 1 | 2006 | 34 | 0.060 |
Why?
|
| Pirenzepine | 1 | 2004 | 2 | 0.060 |
Why?
|
| Muscarinic Antagonists | 1 | 2004 | 18 | 0.050 |
Why?
|
| Pupil | 1 | 2004 | 45 | 0.050 |
Why?
|
| R-SNARE Proteins | 1 | 2003 | 1 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 3 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Synaptic Vesicles | 1 | 2003 | 4 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 24 | 0.050 |
Why?
|
| Presynaptic Terminals | 1 | 2003 | 3 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2003 | 5 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2003 | 31 | 0.050 |
Why?
|
| Picrotoxin | 1 | 2003 | 1 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 4 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2003 | 20 | 0.050 |
Why?
|
| Vitreous Body | 2 | 2008 | 3 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 3 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 17 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 21 | 0.030 |
Why?
|
| Saccades | 1 | 2017 | 16 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 34 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 39 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 1 | 2016 | 18 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 140 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 30 | 0.030 |
Why?
|
| Amacrine Cells | 2 | 2007 | 2 | 0.030 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 2 | 2007 | 2 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 2008 | 3 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2008 | 9 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 28 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 25 | 0.020 |
Why?
|
| Retinal Horizontal Cells | 1 | 2007 | 1 | 0.020 |
Why?
|
| NAV1.2 Voltage-Gated Sodium Channel | 1 | 2007 | 1 | 0.020 |
Why?
|
| NAV1.6 Voltage-Gated Sodium Channel | 1 | 2007 | 1 | 0.020 |
Why?
|
| NAV1.1 Voltage-Gated Sodium Channel | 1 | 2007 | 2 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2007 | 26 | 0.020 |
Why?
|
| Neurons | 1 | 2008 | 109 | 0.020 |
Why?
|
| Lenses | 1 | 2007 | 6 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2007 | 48 | 0.020 |
Why?
|
| Nerve Compression Syndromes | 1 | 2004 | 1 | 0.010 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2004 | 1 | 0.010 |
Why?
|
| Electrodes, Implanted | 1 | 2004 | 11 | 0.010 |
Why?
|
| Carbachol | 1 | 2004 | 8 | 0.010 |
Why?
|
| Ophthalmic Solutions | 1 | 2004 | 7 | 0.010 |
Why?
|
| Conjunctiva | 1 | 2004 | 13 | 0.010 |
Why?
|
| Microelectrodes | 1 | 2004 | 11 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 7 | 0.010 |
Why?
|
| Refraction, Ocular | 1 | 2004 | 127 | 0.010 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2002 | 1 | 0.010 |
Why?
|
| Photoreceptor Cells | 1 | 2002 | 7 | 0.010 |
Why?
|
| Cell Death | 1 | 2002 | 18 | 0.010 |
Why?
|